GLP-1-mediated delivery of tesaglitazar improves obesity and glucose metabolism in male mice
Carmelo Quarta(Université de Bordeaux), Timo D. Müller(Helmholtz Zentrum München), Gustav Colldén(Helmholtz Zentrum München), Aimée Bastidas-Ponce(Helmholtz Zentrum München), Diego Pérez–Tilve(University of Cincinnati Medical Center), Fanny Lalloyer(Inserm), Nathalie Hennuyer(Inserm), Megan E. Capozzi(Duke University), Daniela Liśkiewicz(Helmholtz Zentrum München), Susanna M. Hofmann(Helmholtz Zentrum München), Patrick J. Knerr(Novo Nordisk (United States)), Barent DuBois(Novo Nordisk (United States)), Felix Klingelhuber(University of East Anglia), Gandhari Maity(Helmholtz Zentrum München), Annette Feuchtinger(Helmholtz Zentrum München), Aaron Novikoff(Helmholtz Zentrum München), Arkadiusz Liśkiewicz(Medical University of Silesia), Brian Finan(Novo Nordisk (United States)), Alex Harger(Helmholtz Zentrum München), Daniel J. Drucker(Mount Sinai Hospital), Cristina García‐Cáceres(Helmholtz Zentrum München), Eric Baugé(Inserm), Heiko Lickert(Helmholtz Zentrum München), Perla Cota(Deutsches Diabetes-Zentrum e.V.), Jon Douros(Novo Nordisk (United States)), Bin Yang, Kerstin Stemmer(University of Cincinnati), Jonathan E. Campbell(Duke University), Konxhe Kulaj(Helmholtz Zentrum München), Richard D. DiMarchi(Indiana University Bloomington), Stephan Herzig(Heidelberg University), Natalie Krahmer(Helmholtz Zentrum München), Mostafa Bakhti(Max Planck Institute of Experimental Medicine), Gerald Grandl(Helmholtz Zentrum München), Christoffer Clemmensen(University of Copenhagen), Qian Zhang(Johns Hopkins University), Sneha Prakash(Helmholtz Zentrum München), Miguel A. Sánchez-Garrido(Instituto Maimónides de Investigación Biomédica de Córdoba), Matthias H. Tschöp(University of Cincinnati), Bart Staels(National Institutes of Health)
Cited by 38
Related Papers
Circulating Ghrelin Levels Are Decreased in Human Obesity
|Diabetes|2001|2k
Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease
|Journal of Hepatology|2014|1.5k
Peroxisome Proliferator-activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1
|Journal of Biological Chemistry|1999|1.1k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Anti-obesity drug discovery: advances and challenges
|Nature Reviews Drug Discovery|2021|950